Canada: The Importance Of Product Specificity In The Listing Patents

Last Updated: October 16 2012
Article by Martin P.J. Kratz

The Patented Medicines (Notice of Compliance) Regulations (SOR/93-133) provides the framework for most of Canada's patent litigation. The Patent Act and the PM (NOC) Regulations seek to balance "effective patent enforcement" over new and innovative drugs with the "timely market entry" of lower priced generic versions once the patents have expired. The PM (NOC) Regulations provide innovators of pharmaceutical patents with an ability to list their patents on a Patent List. A generic drug maker who wishes to obtain consent from Health Canada to market a drug based on the same active ingredient (called a Notice of Compliance or NOC) must address the applicable patents on the Patent List. The generic drug maker may address such listed patents by accepting that its product will not receive an NOC until expiry of a listed patent, or may assert that its product would not infringe the claims of such listed patent or may challenge the validity of a listed patent.

The PM (NOC) Regulations further provide the innovator with an extraordinary remedy – if the generic makes assertions of non-infringement or invalidity the application for judicial review of such assertions gives the innovator an automatic two-year stay of the decision of Health Canada to issue the NOC – without having to satisfy the normal requirements for injunctive relief otherwise provided by law. During that two-year period the parties litigate the issues raised by the generic's allegations.

One can see, therefore, that it is therefore of extraordinary importance to determine whether or not a patent may be properly listed on the Patent List. There must be a rational connection between the patents so listed and the regulatory submissions of the innovator against which the patents are submitted. The PM (NOC) Regulations provide the rules for assessing what patents may be listed. Given that there is so much litigation under the PM (NOC) Regulations it is important to have a clear understanding of the applicable rules.

The Federal Court of Appeal had a recent opportunity to consider and provide clarity to these rules in Gilead Sciences Canada Inc. v. Canada (Health) , 2012 FCA 254.

Gilead had sought to list Patent 2,512,475 ( '475 Patent) in respect of a New Drug Submission (NDS) (the process by which the innovator seeks to obtain an NOC for the applicable drug) seeking approval of a drug for the treatment of human immunodeficiency virus (HIV) infection. The NDS stated that the drug, known as Complera, contained the medicinal ingredients: tenofovir, emtricitabine, and rilpivirine. The '475 Patent claimed chemically stable characteristics of tenofovir and emtricitabine in combination and sometimes with a third medicinal ingredient. The '475 Patent did not claim rilpivirine.

The listing criteria require that to be eligible for listing the patent must contain, under section 4(2)(a), "a claim for the medicinal ingredient" or under section 4(2)(b) "a claim for the formulation that contains the medicinal ingredient", in either case where the medicinal agreement or formulation had been approved through the issuance of an NOC in respect of the Submission.

Gilead claimed listing of the '475 Patent under either section 4(2)(a) or 4(2)(b).

The Minister of Health refused to list the '475 Patent on the Patent Register as, in his view, it did not meet the requirements of section 4(2)(b) that require that, to be eligible for listing, the patent must contain "a claim for the formulation that contains the medicinal ingredient and the formulation has been approved through the issuance of a notice of compliance in respect of the Submission."

The Minister found that the medicinal ingredients claimed in the '475 Patent did not match up with those in the NDS. The Minister found that "a patent containing claims for a formulation cannot 'match' the approved formulation unless both formulations explicitly contain all of the same medicinal ingredients." The Minister found that the '475 Patent did not meet the "matching requirement" for lack of product specificity. Gilead sought judicial review.

The test for judicial review of the Minister's decision required the Federal Court to assess: (1) the correct construction of the '475 Patent; (2) the proper interpretation of sections 4(2)(a) and (b) of the PM (NOC) Regulations; and, (3) whether the Minister's decision to exclude the '475 Patent from the Register was reasonable.

The Federal Court accepted the Minister's position and dismissed Gilead's application for judicial review. The Federal Court had found that that the object of the invention was to take advantage of the chemically stable characteristics of tenofovir and emtricitabine in combination and sometimes with a third medicinal ingredient.

While there was no dispute with the construction of the claims, the Federal Court had jumped directly to describe these claims in comparison with the three ingredients contained in Complera, without interpreting both sections 4(2)(a) and (b) to assess whether the claims fell more appropriately under (a) or (b).

The FCA found that both the Minister and the Judge failed to give sufficient weight to the requirement that formulations, by definition, contain non-medicinal ingredients and set out a particular dosage form, which is administered to the patient. In the case of the '475 Patent it was clear that the relevant claims did not meet the definition of "formulation", because they did not contain non-medicinal ingredients. The FCA rejected the argument that claims to a combination of medicinal ingredients was a "formulation of the separate medicinal ingredients into the new combination product" as the definition of "formulation" in the PM (NOC) Regulations is clear and must contain both medicinal and non-medicinal ingredients.

Here, since the '475 Patent did not claim a formulation and only claimed medicinal ingredients, the '475 Patent should properly have been considered by the Minister or the Federal Court under section 4(2)(a) which deals with claims to medicinal ingredients.

Gilead argued for a low threshold of connection between the wording of the NDS and the patent claim and also that the PM (NOC) Regulations must be given a broad interpretation.

The FCA rejected these arguments noting that it had confirmed in Purdue Pharma v. Canada (Attorney General), 2011 FCA 132, dealing with another subsection of the PM (NOC) Regulations, that absent precise and specific matching between the patent claims and the approved NOC, the patent waas not eligible for listing. The FCA noted that the wording of section 4 is consistent across the four subsections and requires a high degree of specificity between the wording of the claim and the NOC.

The FCA affirmed the Federal Court's reasoning on product specificity that "the claimed formulation and the approved formulation do not match precisely and the requirement of product specificity is not met" and then considered the '475 Patent under section 4(2)(a). In conclusion the FCA upheld the Judge's conclusion that the patent claims fail the requirement for product specificity because they do not make specific reference to the medicinal ingredient rilpirivine, but only the broad class of compounds, but the FCA did so under section 4(2)(a) rather than 4(2)(b).

The Gilead decision reinforces the importance of strict compliance with the listing requirements under the PM (NOC) Regulations. This strict approach to addressing the listing requirements is consistent with the policy, set out in the RIAS underlying the 2006 amendments to the PM (NOC) Regulations, that where the patent fails to meet the listing requirements, policy considerations tip the balance in favour of the generic manufacturer, and the matter is better left to the alternative (and traditional) judicial recourse of an infringement action. It is worth remembering that the PM (NOC) Regulations are an exceptional process and provide unusual rights to the patent owner additional to the rights provided to all patent owners under patent law.

A version of this article will be published in SLAW.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Martin P.J. Kratz
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.